PMID- 34661257
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20221207
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 25
IP  - 19
DP  - 2021 Oct
TI  - Impact of Glycated Hemoglobin (HbA1c) on cognitive functions in Type 2 diabetic 
      patients.
PG  - 5978-5985
LID - 26875 [pii]
LID - 10.26355/eurrev_202110_26875 [doi]
AB  - OBJECTIVE: Diabetes mellitus is a highly challenging worldwide epidemic affecting 
      the health of millions of people. This study investigates the impact of glycated 
      hemoglobin (HbA1c) and duration of diabetes on cognitive functions in type 2 
      diabetic patients and evaluates whether high HbA1c or duration is more harmful to 
      impair cognitive functions. PATIENTS AND METHODS: In this study, 202 
      participants, 101 patients with type 2 diabetes mellitus (T2DM), and 101 age, 
      gender, height, and weight-matched controlled subjects were enlisted. The HbA1c 
      was determined using a clover analyzer, and cognitive functions were evaluated 
      using "Cambridge Neuropsychological Test Automated Battery (CANTAB). RESULTS: The 
      results revealed that AST Mean correct latency, AST Mean correct latency 
      (congruent), AST Mean correct latency (incongruent), CRT Mean correct latency, 
      MOT Mean latency, SWM Between errors, SWM Strategy, PRM Percent correct responses 
      were meaningly delayed in the diabetic group as compared to the control group (p 
      < 0.0001). CONCLUSIONS: High HbA1c or uncontrolled DM and duration of diabetes 
      cause cognitive function impairment. Moreover, the cognitive functions declined 
      were significantly linked with the duration of the disease and high HbA1c. While 
      treating diabetic patients, physicians must monitor the HbA1c level as reasonable 
      glycemic control is vital to curtail the complications of DM, including cognitive 
      function impairment.
FAU - Maan, H B
AU  - Maan HB
AD  - Department of Physiology, College of Medicine, King Saud University, Riyadh, 
      Saudi Arabia. smeo@ksu.edu.sa.
FAU - Meo, S A
AU  - Meo SA
FAU - Rouq, F A
AU  - Rouq FA
FAU - Meo, I M U
AU  - Meo IMU
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Case-Control Studies
MH  - Cognition/physiology
MH  - Cognitive Dysfunction/blood/*epidemiology/etiology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/*psychology
MH  - Female
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Time Factors
EDAT- 2021/10/19 06:00
MHDA- 2022/03/24 06:00
CRDT- 2021/10/18 09:19
PHST- 2021/10/18 09:19 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
AID - 26875 [pii]
AID - 10.26355/eurrev_202110_26875 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):5978-5985. doi: 
      10.26355/eurrev_202110_26875.